関連する実験動画
Updated: May 6, 2026
08:41
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
8.6K
TFEBは,化学療法剤CX-5461に対する耐性を付与する
Marjorie Rolland1, Benoît Marchand1, Laure Bessy1
1Department of Medicine, Gastroenterology Unit, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke Cancer Research Institute (IRCUS), Université de Sherbrooke, Sherbrooke, Canada.
Autophagy reports
|February 20, 2026
まとめ
ガン細胞はゲムシタビンに反応して,転写因子EB (TFEB) を介して保護信号を活性化します. TFEBのターゲティングは,化学療法に対する感受性を高め,化学抵抗に対する新しい戦略を提供します.
科学分野:
- 細胞生物学 細胞生物学
- 分子腫瘍学 分子腫瘍学
- ドラッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー
背景:
- 化学抵抗は,がん治療の有効性を制限する.
- 転写因子EB (TFEB) はオートファジーとリソソームバイオゲネシスを調節し,細胞のストレス反応に役割を果たします.
- 化学療法薬であるジェムシタビンは,TFEBに依存する保護信号を誘発しますが,誘発メカニズムは不明です.
研究 の 目的:
- 核ストレスに対するゲムシタビンの効果を調査する.
- 核ストレス誘発剤がTFEB依存の保護経路を活性化するかどうかを判断する.
- 化学抵抗を克服するためのターゲットとしてTFEBを探求する.
主な方法:
- ガン細胞をゲムシタビンと核ストレス剤CX-5461で治療する.
- 核子ストレスマーカーの評価.
- TFEBの核転移に関する分析.
- TFEBの干渉に対する癌細胞の感受性の評価.
主要な成果:
- ゲムシタビンは核ストレスを誘発することが確認されました.
- 核ストレス剤CX-5461は,TFEB核の蓄積を促した.
- TFEBの機能を妨害すると,ガン細胞はゲムシタビンとCX-5461の両方に敏感になる.
- TFEBの活性化により,化学療法によるストレスから広範な保護が得られます.
結論:
- TFEBの活性化は,化学療法によって引き起こされる細胞のストレスに対する保護的メカニズムを提供します.
- TFEBをターゲットにすることで,化学療法剤に対するがん細胞の感受性を高めることができます.
- TFEBは,抗がん薬の有効性を向上させ,化学抵抗を克服するための潜在的な治療目標です.
関連する概念動画
02:57Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
02:56Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84